INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Fluent in reading and writing in English language │ Fluent in reading and writing in English language │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ ≥ 21 years of age at the time of participation    │ = 21 years of age at the time of participation    │      98 │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Presence if contraindications for treatment with   │ Fluent in reading and writing in English language │      14 │
│ H.P. Acthar gel including but not limited to any   │                                                   │         │
│ known history of scleroderma, osteoporosis,        │                                                   │         │
│ systemic fungal infections, ocular Herpes Simplex, │                                                   │         │
│ recent administration of live or live attenuated   │                                                   │         │
│ vaccine (prior 6 months), recent surgery (prior 6  │                                                   │         │
│ months), history of or the presence of a peptic    │                                                   │         │
│ ulcer, primary adrenocortical insufficiency,       │                                                   │         │
│ adrenal cortical hyperfunction; congestive heart   │                                                   │         │
│ failure (defined as New York Hear Association      │                                                   │         │
│ Functional Class I to IV, uncontrolled             │                                                   │         │
│ hypertension                                       │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with diagnosis of RA with incomplete or   │ Fluent in reading and writing in English language │      20 │
│ failure to treatment described as either A or B A: │                                                   │         │
│ Failure to achieve remission or low disease        │                                                   │         │
│ activity within 3 to 6 months of treatment with    │                                                   │         │
│ combination of methotrexate or other DMARDs        │                                                   │         │
│ therapy with a biologic DMARD in maximally         │                                                   │         │
│ tolerated doses within the usual therapeutic range │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Pregnancy                                          │ Fluent in reading and writing in English language │      21 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ B- A requirement, in addition to DMARDs and        │ Fluent in reading and writing in English language │      23 │
│ biologic DMARDs, for chronic glucocorticoid        │                                                   │         │
│ therapy in a dose of greater than about 5 to 7.5   │                                                   │         │
│ mg/day of prednisone or equivalent to achieve or   │                                                   │         │
│ maintain remission or low disease activity after 3 │                                                   │         │
│ to 6 months of treatment                           │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Previous use of ACTH preparations for treatment of │ Fluent in reading and writing in English language │      34 │
│ nephrotic syndrome (including but not limited to   │                                                   │         │
│ H.P. Acthar gel and Synacthen®)                    │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Previous history of sensitivity to ACTH            │ Fluent in reading and writing in English language │      36 │
│ preparations (including but not limited to H.P.    │                                                   │         │
│ Acthar gel and Synacthen®)                         │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 21 Years                  │ = 21 years of age at the time of participation    │      38 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Previous history of sensitivity to porcine protein │ = 21 years of age at the time of participation    │      40 │
│ products                                           │                                                   │         │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria   │   Score │
╞════════════════════════════════════════════════════╪═════════════════╪═════════╡
│ Previous use of ACTH preparations for treatment of │ NA              │       2 │
│ nephrotic syndrome (including but not limited to   │                 │         │
│ H.P. Acthar gel and Synacthen®)                    │                 │         │
╘════════════════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 12
Average Levenshtein Ratio of individual lines: 38.72727272727273
OverAll Ratio: 25.363636363636363
